Recent news on Pegfilgrastim

Roche launches Neulastim  -  May 9, 2007
Express Pharma,Roche has announced the availability of the drug Neulastim (pegfilgrastim) in India. Neulastim, administered as a single fixed dose per chemotherapy cycle,

Research and Markets: In 2005, Sepracor's New Insomnia Drug ...  -  Apr 27, 2007
PharmaLive.com (press release),Between 2001 and 2005, the leading new drug launch by first year sales was Amgen's Neulasta (pegfilgrastim) with US$722 million, followed by Genentech/

Roche brings Neulastim (pegfilgrastim) to India  -  Apr 7, 2007
Moneycontrol.com,Roche Scientific Company ( India ) Pvt. Ltd. today announced the availability of the drug Neulastim ® (pegfilgrastim) in India .

Amgen posts strong results after Aranesp relief  -  Apr 24, 2007
BiopharmaReporter.com,...increased competition - while white blood cell boosters Neupogen (fligrastim) and Neulasta (pegfilgrastim) saw combined sales jump 14 per cent to $1bn.

Amgen's First Quarter 2007 Revenue Increased 15 Percent to $3.7 ...  -  Apr 23, 2007
Genetic Engineering News (press release),Combined worldwide sales of Neulasta(R) (pegfilgrastim) and NEUPOGEN(R) (Filgrastim), increased 14 percent to $1018 million in the first quarter of 2007

Keeping the atmosphere — and the mind — calm  -  Apr 18, 2007
Ithaca Journal,These items are adorned with zippy company drug names like “Anzemet (dolasetron mesylate injection/tablets),� “Neulasta (pegfilgrastim),� “Sanofi Aventis,�

Dose-intensive Chemotherapy Improves Survival for Patients with ...  -  Feb 2, 2007
Cancer Consultants (press release),To counter these potentially life-threatening side effects, agents such as Neulasta® (pegfilgrastim) or Neupogen® (filgrastim) are often used.

Aranesp Data Eclipse Amgen's Fourth-Quarter Revenue Growth  -  Jan 26, 2007
BioWorld Online,And combined worldwide sales of Amgen's neutropenia drugs, Neulasta (pegfilgrastim) and Neupogen (filgrastim) increased 10 percent to $1 billion for the

Sprycel® Superior to High-Dose Gleevec for Gleevec-Resistant CML  -  18 Jan 2007
Cancer Consultants (press release),...the main side effect of Sprycel was cytopenias that could be corrected by the administration of Neupogen® (filgrastim) or Neulasta® (pegfilgrastim).

Low Incidence of Neutropenic Complications Among NHL and HL ...  -  18 Jan 2007
Cancer Consultants (press release),These same authors have now reported the outcomes of a prospective community-based study evaluating the efficacy of first cycle Neulasta (pegfilgrastim) in

Early Use of Neulasta Reduces Complications from Neutropenia in ...  -  Jan 5, 2007
Cancer Consultants (press release),According to results recently presented at the 2006 annual meeting of the American Society of Hematology, the use of Neulasta® (pegfilgrastim) during the

Kepivance® May Decrease Oral Mucositis Following High-dose ...  -  Jan 10, 2007
Cancer Consultants (press release),Researchers from Germany reported the results of combining Kepivance and Neulasta® (pegfilgrastim) in patients with multiple myeloma receiving high-dose

Kepivance® May Decrease Oral Mucositis Following High-Dose ...  -  Jan 8, 2007
Cancer Consultants (press release),Researchers from Germany reported the results of combining Kepivance and Neulasta® (pegfilgrastim) for the prophylaxis of patients with multiple myeloma

Research and Markets: Gain an Insight into the Financial ...  -  Dec 20, 2006
PharmaLive.com (press release),Neulasta (pegfilgrastim) is a sustained-duration formulation of Neupogen (filgrastim) formed by the addition of polyethylene glycol to granulocyte colony

Research and Markets: Gain an Insight into the Financial ...  -  Dec 20, 2006
PharmaLive.com (press release),Neulasta (pegfilgrastim) is a sustained-duration formulation of Neupogen (filgrastim) formed by the addition of polyethylene glycol to granulocyte colony

Neulasta® Safe and Effective for Hodgkin’s Patients Treated ...  Nov 7, 2006
...patients treated with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy every two weeks, use of Neulasta® (pegfilgrastim) was safe and ... -Cancer Consultants (press release), Findings from Germany, Netherlands and the United States in cancer ...  Oct 19, 2006
Study 1: Single-dose pegfilgrastim after chemotherapy induces stem cell mobilization in malignant lymphoma or multiple myeloma patients. ... -Therapeutics Daily (subscription) (press release), Amgen's Third Quarter 2006 Adjusted Earnings Per Share, Excluding ...  Oct 23, 2006
Combined worldwide sales of Neulasta(R) (pegfilgrastim) and NEUPOGEN(R) (Filgrastim), increased 13 percent to $998 million in the third quarter of 2006 versus ... -Genetic Engineering News (press release), Consider the Integration of Pharmacokinetic & Pharmacodynamic ...  Oct 17, 2006
...drug development plan, taking as case studies the preclinical and clinical drug development of tasidotin, as well as the examples of cetuximab and pegfilgrastim ... -Genetic Engineering News (press release), Health Canada-Approved Treatment Reduces Potentially Fatal ...  Sep 13, 2006
MISSISSAUGA, CANADA -- September 13, 2006 -- Results from a study on the early administration of Neulasta® (pegfilgrastim) in breast cancer patients receiving ... -DG News

Protecting Against Serious Chemotherapy Side Effect  Aug 20, 2006
For instance, Neulasta® (pegfilgrastim), a medication that increases white blood cell count, administered from the first cycle of chemotherapy treatment ... -HealthNewsDigest.com

Neupogen® Decreases Toxicities Associated with Taxotere® ...  Aug 3, 2006
The administration of prophylactic Neupogen or Neulasta® (pegfilgrastim) to patients receiving chemotherapy accelerates neutrophil recovery, decreases the ... -Cancer Consultants

DME: Lifecycle management for biologics  Aug 2, 2006
Rituxan (rituximab), while Maxygen is targeting G-CSF, a treatment currently dominated by Amgen's Neupogen (filgrastim)/Neulasta (pegfilgrastim) for enhancement ... -PharmaLive.com

Caution Urged in Use of G-CSF with Chemo in Early Breast Cancer  Jul 21, 2006
...note. "The long-term effects of pegfilgrastim used during dose-dense regimens must be monitored cautiously," Dr. Ferretti concluded. ... -Cancerpage.com

High-dose Dense Chemotherapy and Radiation Therapy for Women with ...  Jul 21, 2006
...related news). Dose-dense regimens are usually supported by Neupogen® (filgrastim) or Neulasta® (pegfilgrastim). However, one ... -Cancer Consultants

Amgen's Second Quarter 2006 Adjusted Earnings Per Share  Jul 21, 2006
Combined worldwide sales of Neulasta(R) (pegfilgrastim) and NEUPOGEN(R) (Filgrastim), increased 12 percent to $1,005 million in the second quarter of 2006 ... -boerse.de (Pressemitteilung)

ASCO Guidelines for Use of White Blood Cell Growth Factors ...  Jul 19, 2006
...the 2006 update of recommendations for the use of white blood cell growth factors such as Neupogen® (filgrastim) or Neulasta® (pegfilgrastim) for prevention ... -Cancer Consultants

Guidelines Address Prevention of Neutropenia  Jul 13, 2006
For patients at high risk of developing neutropenia, blood cell growth factors such as Neulasta® (pegfilgrastim) can be used to reduce the risk. ... -Cancer Consultants

Neulasta® Granted Expanded Indication  Jun 30, 2006
Amgen Inc.’s growth factor Neulasta (pegfilgrastim) has been granted an expanded indication by the Food and Drug Administration (FDA). ... -Cancer Consultants



Research and Markets: Aranesp, Neulasta and Enbrel have all Shown ...  16 May 2006
Neulasta (pegfilgrastim) is a sustained-duration formulation of Neupogen (filgrastim) formed by the addition of polyethylene glycol to granulocyte colony ... - Genetic Engineering News

Dose-Dense Therapy for NHL Safely Administered with Support of ...  Apr 18, 2006
Among patients with diffuse large B-cell lymphoma, supportive treatment with Neulasta® (pegfilgrastim) allowed for the safe administration of the dose-dense ... - Cancer Consultants

Dose-Dense Adjuvant Chemotherapy for Node-Positive Breast Cancer ...  May 5, 2006
...effect of suppressed blood cell production, researchers have administered a granulocyte colony-stimulating factor, such as Neupogen or Neulasta® (pegfilgrastim ... - Cancer Consultants

Amgen's First Quarter 2006 Adjusted Earnings per Share, Excluding ...  Apr 20, 2006
Combined worldwide sales of Neulasta(R) (pegfilgrastim) and NEUPOGEN(R) (Filgrastim), increased 13 percent to $896 million in the first quarter of 2006 versus ... - Webbolt Business News

Further Evidence that Chemotherapy-Induced Neutropenia Results in ...  Apr 17, 2006
Agents such as Neulasta® (pegfilgrastim), which can prevent chemotherapy-induced neutropenia, may play an important role for patients with cancer. ... - Cancer Consultants





Long-Term Study Shows Safety of Neupogen® Support in AML ...  Mar 17, 2006
However, this study clearly demonstrates that Neupogen, and by extrapolation the more commonly used Neulasta® (pegfilgrastim), can be used safely in patients ... - Cancer Consultants

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional